参考文献/References:
[1] Badr K, Wainwright CL. Inflammation in the cardiovascular system:here,there and everywhere[J]. Curr Opin Pharmacol,2004,4(2):107-109.
[2] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J]. Cell, 2006,124(4):783-801.
[3] Lin Y, Verma A, Hodgkinson CP. Toll-like receptors and human disease:lessons from single nucleotide polymorphisms[J]. Curr Genomics,2012,13(8):633-645.
[4] Wang Y, Ge P, Zhu Y. TLR2 and TLR4 in the brain injury caused by cerebral ischemia and reperfusion[J]. Mediators Inflamm,2013,2013:124614.
[5] Akira S, Takeda K. Toll-like receptor signalling[J]. Nat Rev Immunol,2004,4(7):499-511.
[6] Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors(TLR)in human leukocytes:selective expression of TLR3 in dendritic cells[J]. J Immunol,2000,164(11):5998-6004.
[7] Cole JE, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis[J]. Mediators Inflamm,2010,2010:393946.
[8] Yamamoto M, Akira S. Mechanisms of innate immune responses mediated by Toll-like receptors[J]. Clin Appl Immunol Rev,2005,5(3):167-183.
[9] Park BS, Lee J. Recognition of lipopolysaccharide pattern by TLR4 complexes[J]. Exp Mol Med, 2013,45:e66. doi: 10.1038/emm.2013.97.
[10] 朱杰,朴荣利,高润平.TLR4信号传导通路与胰腺炎[J].世界华人消化杂志,2012,(4):271-275.
[11] Pålsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4[J]. Immunology, 2004,113(2):153-162.
[12] Lucas K, Maes M. Role of the Toll like receptor(TLR)radical cycle in chronic inflammation:possible treatments targeting the TLR4 pathway[J]. Mol Neurobiol, 2013,48(1):190-204.
[13] Liu N, Montgomery RR, Barthold SW, et al. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice[J]. Infect Immun,2004,72(6):3195-3203.
[14] Downes CE, Crack PJ. Neural injury following stroke:are Toll-like receptors the link between the immune system and the CNS?[J]. Br J Pharmacol,2010,160(8):1872-1888.
[15] Wang Y, Lin S, Yang Q. Toll-like receptors in cerebral ischemic inflammatory injury[J]. J Neuroinflammation,2011,8(134):554-561.
[16] Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling[J]. Nature,2003,424(6950):743-748.
[17] Wu D, Lee YG, Liu H, et al. Identification of TLR downstream pathways in stroke patients[J]. Clin Biochem,2013,46(12):1058-1064.
[18] Tuttolomondo A, di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease[J]. Curr Pharm Des,2012,18(28):4266-4288.
[19] Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways[J]. Inflamm Res,2010,59(10):791-808.
[20] Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E[J]. Proc Natl Acad Sci USA,2004,101(29):10679-10684.
[21] Chávez-Sánchez L, Garza-Reyes MG, Espinosa-Luna JE, et al. The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans[J]. Hum Immunol,2014,75(4):322-329.
[22] Cole JE, Mitra AT, Monaco C. Treating atherosclerosis:the potential of Toll-like receptors as therapeutic targets[J]. Expert Rev Cardiovasc Ther,2010,8(11):1619-1635.
[23] Lu Z, Zhang X, Li Y, et al. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice[J]. J Endocrinol,2013,216(1):61-71.
[24] Yonekawa K, Neidhart M, Altwegg LA, et al. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes[J]. Atherosclerosis,2011,218(2):486-492.
[25] Katsargyris A, Klonaris C, Tsiodras S, et al. Statin treatment is associated with reduced toll-like receptor 4 immunohistochemical expression on carotid atherosclerotic plaques:a novel effect of statins[J]. Vascular,2011,19(6):320-326.
[26] Eissler R, Schmaderer C, Rusai K, et al. Hypertension augments cardiac Toll-like receptor 4 expression and activity[J]. Hypertens Res,2011,34(5):551-558.
[27] Ji Y, Liu J, Wang Z, et al. Angiotensin Ⅱ induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells[J]. Cell Physiol Biochem,2009,23(4-6):265-276.
[28] Bomfim GF, Dos Santos RA, Oliveira MA, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats[J].Clin Sci(Lond),2012,122(11):535-543.
[29] 卢文,刘淑华,赵志明,等.高血压患者TLR4和胱抑素C的水平变化及作用[J].临床肾脏病杂志,2013,13(11):500-505.
[30] 陈思,周忠,景胜.高血压病患者外周血Toll样受体-4及细胞毒T淋巴细胞相关抗原-4 的表达及临床意义[J]. 实用医学杂志,2014,30(22):3601-3603.
相似文献/References:
[1]汪汉,综述.显微镜下多血管炎的心血管病变[J].心血管病学进展,2016,(2):170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.019]
WANG Han.Cardiovascular Involvement in Microscopic Polyangitis[J].Advances in Cardiovascular Diseases,2016,(1):170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.019]
[2]汪汉,综述.几种少见的风湿性疾病的心血管表现[J].心血管病学进展,2016,(3):305.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.024]
WANG Han.Cardiovascular Manifestations in Rare Rheumatic Diseases[J].Advances in Cardiovascular Diseases,2016,(1):305.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.024]
[3]李子进,综述,李景东,等.锚蛋白B在心血管系统中作用的研究进展[J].心血管病学进展,2016,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
LI Zijin,LI Jingdong.Research Progress of Ankyrin-B in Cardiovascular System[J].Advances in Cardiovascular Diseases,2016,(1):341.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
[4]万永伦,综述,高倩萍,等.红细胞分布宽度与心血管疾病之间的病理生理联系[J].心血管病学进展,2016,(4):387.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.016]
WAN Yonglun,GAO Qianping.Pathophysiological Connection Between Red Blood Distribution
Width and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2016,(1):387.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.016]
[5]孟雅洁,综述,付真彦,等.芳香化酶基因与心血管相关疾病的研究进展[J].心血管病学进展,2016,(4):405.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.020]
MENG Yajie,FU Zhenyan.Progress in Research of the Relationship Between CYP19A1
Gene and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):405.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.020]
[6]冉丹,佘强.载脂蛋白C-Ⅲ在心血管疾病中的研究进展[J].心血管病学进展,2015,(5):613.[doi:10.3969/j.issn.1004-3934.2015.05.023]
RAN Dan,SHE Qiang.Progress of Apolipoprotein C-Ⅲ in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2015,(1):613.[doi:10.3969/j.issn.1004-3934.2015.05.023]
[7]隆雪原,罗素新.睡眠与心血管疾病相互关系的研究进展[J].心血管病学进展,2015,(6):735.[doi:10.3969/j.issn.1004-3934.2015.06.020]
LONG Xueyuan,LUO Suxin.Research Progress of the Relationship Between Sleep and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(1):735.[doi:10.3969/j.issn.1004-3934.2015.06.020]
[8]李涛 杨思姝 钱永军.纳米技术在心血管疾病中的最新应用[J].心血管病学进展,2019,(5):708.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.012]
LI Tao,YANG Sishu,QIAN Yongjun.Nanotechnology in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):708.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.012]
[9]潘乐 汪翔 龚惠.单细胞测序在心血管系统中的应用[J].心血管病学进展,2020,(12):1227.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.001]
PAN Le,WANG Xiang,GONG Hui.Application of single cell sequencing in cardiovascular system[J].Advances in Cardiovascular Diseases,2020,(1):1227.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.001]
[10]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]